WO2001082912A3 - TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE - Google Patents

TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE Download PDF

Info

Publication number
WO2001082912A3
WO2001082912A3 PCT/IB2001/000715 IB0100715W WO0182912A3 WO 2001082912 A3 WO2001082912 A3 WO 2001082912A3 IB 0100715 W IB0100715 W IB 0100715W WO 0182912 A3 WO0182912 A3 WO 0182912A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
phanquinone
mmps
action
pathological conditions
Prior art date
Application number
PCT/IB2001/000715
Other languages
French (fr)
Other versions
WO2001082912A2 (en
Inventor
Michel Xilinas
Original Assignee
Michel Xilinas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel Xilinas filed Critical Michel Xilinas
Priority to AU2001250573A priority Critical patent/AU2001250573A1/en
Publication of WO2001082912A2 publication Critical patent/WO2001082912A2/en
Publication of WO2001082912A3 publication Critical patent/WO2001082912A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A use of phanquinone for the manufacture of a pharmaceutical composition for the prevention or the treatment of pathological conditions influenced by the action of matrix metalloproteinases (MMPs) is disclosed. Also methods of treatment or prevention of such conditions are disclosed.
PCT/IB2001/000715 2000-04-28 2001-04-30 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE WO2001082912A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001250573A AU2001250573A1 (en) 2000-04-28 2001-04-30 Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200000704 2000-04-28
DKPA200000704 2000-04-28

Publications (2)

Publication Number Publication Date
WO2001082912A2 WO2001082912A2 (en) 2001-11-08
WO2001082912A3 true WO2001082912A3 (en) 2002-05-16

Family

ID=8159457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000715 WO2001082912A2 (en) 2000-04-28 2001-04-30 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE

Country Status (2)

Country Link
AU (1) AU2001250573A1 (en)
WO (1) WO2001082912A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574218B2 (en) 2001-01-19 2017-02-21 Phyton Holdings, Llc Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002526B1 (en) 1997-08-21 2002-06-27 П.Н.Геролиматос С.А. Use of phanquinone for the treatment of alzheimer's disease
EP2264177B1 (en) 1998-12-09 2015-09-30 Phyton Holdings, LLC Glycoproteins having human-type glycosylation
NZ518532A (en) 1999-10-26 2004-02-27 Plant Res Internat B Transgenic plant expressing mammalian beta-1,4- galactosyltransferase
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
CA2819867A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants
AR042145A1 (en) 2002-11-27 2005-06-08 Dow Agrociences Llc IMMUNOGLOBULIN PRODUCTION IN PLANTS WITH A REDUCED FUCOCILATION
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
EP2147108B1 (en) 2007-04-17 2014-03-05 Stichting Dienst Landbouwkundig Onderzoek Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009981A1 (en) * 1997-08-21 1999-03-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
WO2000040244A1 (en) * 1999-01-07 2000-07-13 P.N. Gerolymatos S.A. Use of phanquinone for the treatment or prevention of memory impairment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009981A1 (en) * 1997-08-21 1999-03-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
WO2000040244A1 (en) * 1999-01-07 2000-07-13 P.N. Gerolymatos S.A. Use of phanquinone for the treatment or prevention of memory impairment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574218B2 (en) 2001-01-19 2017-02-21 Phyton Holdings, Llc Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain

Also Published As

Publication number Publication date
WO2001082912A2 (en) 2001-11-08
AU2001250573A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
WO2002046129A3 (en) Inhibitors of histone deacetylase
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CY1112932T1 (en) Suspensions SMAD7 FOR CNS DISEASE TREATMENT
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO2001098236A3 (en) 7-phenyl-substituted tetracycline compounds
EA200100804A1 (en) SULPHOOROMATIC DERIVATIVES OF HYDROXAMIC ACID AS METHYPE PROTEASIS INHIBITORS
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
WO2004058185A3 (en) Antiangiogenesis by inhibiting protein kinase ck2 activity
WO2002020475A3 (en) Inhibitors of serine protease activity of matriptase or mtsp1
NO983991L (en) Serine protease inhibitors
WO2002080853A3 (en) Fused heterocyclic inhibitors of factor xa
WO2001082912A3 (en) TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING PHANQUINONE
WO2003016248A3 (en) Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
WO2003099202A3 (en) Beta-secretase inhibitors
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2001082911A3 (en) TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
WO2003051838A3 (en) Protein kinase inhibitors
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2002006480A3 (en) Tissue inhibitors of matrix metalloproteinases
WO2003011309A3 (en) Pharmaceutical composition for treating hypercholesterolaemia
WO2003000269A3 (en) Novel use for pde 10a inhibitors
WO2002055081A3 (en) Use of chelators in the treatment of macular degenerative disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP